4-(氨基甲基)-1-异丙基-哌啶-4-醇 | 132740-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(氨基甲基)-1-异丙基-哌啶-4-醇
• 英文名称: 4-(Aminomethyl)-1-(propan-2-yl)piperidin-4-ol
• 英文别名: 4-(aminomethyl)-1-propan-2-ylpiperidin-4-ol
• CAS: 132740-55-7
• 化学式: C₉H₂₀N₂O
• mdl: MFCD12169415
• 分子量: 172.27
• InChiKey: DAMMODNJHFWQSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
  申请人：Agency for Science, Technology and Research

  公开号：US20140371199A1

  公开（公告）日：2014-12-18

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：Marmsater Fredrik P.

  公开号：US20100144751A1

  公开（公告）日：2010-06-10

  Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.

  化学式（I）的化合物是受体酪氨酸激酶抑制剂，可用于治疗由类（3）和类（5）受体酪氨酸激酶介导的疾病。该发明的特定化合物也被发现是Pim-1的抑制剂。
• BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
  申请人：Agency for Science, Technology and Research

  公开号：US20150038506A1

  公开（公告）日：2015-02-05

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.

  本发明涉及某些化合物（例如，咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），它们作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物制备预防和治疗疾病（例如增生性疾病（例如癌症），神经退行性疾病（例如阿尔茨海默病），代谢性疾病（例如糖尿病），神经发育障碍（例如自闭症），或精神障碍（例如精神分裂症或焦虑症））的药物以及治疗这些疾病的方法。
• New piperidine derivatives as antihistaminics
  申请人：FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES)

  公开号：EP0385044A1

  公开（公告）日：1990-09-05

  New antihistaminic piperidine derivatives of general structural formula I are prepared by reacting 4-­piperidinealkylamines with carboxylic acids or their active derivatives, such as lower-alkyl esters or the acid chlorides. The obtained new piperidine carboxamide compounds show potent antihistaminic activity as specific antagonists of histamine H1-receptors.

  通过 4-哌啶烷基胺与羧酸或其活性衍生物（如低级烷基酯或酸氯化物）反应，制备出结构通式 I 的新型抗组胺哌啶衍生物。 所获得的新哌啶甲酰胺化合物作为组胺 H1 受体的特异性拮抗剂，显示出强大的抗组胺活性。
• Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
  申请人：Agency for Science, Technology and Research

  公开号：US10280168B2

  公开（公告）日：2019-05-07

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazopyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.

  本发明涉及某些作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂的化合物（例如咪唑吡嗪、咪唑吡啶、咪唑哒嗪和咪唑嘧啶化合物）。本发明进一步涉及包含这些化合物的药物组合物，以及这些化合物用于制备预防和治疗疾病（如增殖性疾病（如癌症）、神经退行性疾病（如阿尔茨海默病）、代谢性疾病（如糖尿病）、神经发育障碍（如自闭症）或精神障碍（如精神分裂症或焦虑症））的药物以及治疗这些疾病的方法。